Salt Composition in both
Ciprofloxacin 500mg + Tinidazole 600mg
Salt Composition
(same for both)
You Searched
Strip of 8 tablets
We only sell the best substitute from top brands
Our Recommendation
Florentine Tablet 1000mg 8s
Strip of 1000 tablets
1,824+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Yes! life! TNS Lifezez is proud to presentTNS Lifezezto help you save more than 50% on life-long supply oftolerable, life-proventolerable, life-proven antibiotic, HIV-1 and AIDS medication.
This leaflet does not contain all the information that is listed above.
You should always speak to your doctor or pharmacist before taking any medicine.There are many different antibiotics available
There is not enough information to recommend ciprofloxacin for the treatment of bacterial infections. There are certain infections that may need to be treated with this medicine. Other medicines that may be prescribed for such infections are ciprofloxacin (cipro), cefuroxime (cipro), cefpodoxime (cipro), cefpodoxime-flosup (cipro), erythromycin (cipro), metronidazole (cipro), metronidazole-rs (cipro), nafcillin/clavulanate (cipro), nelfinavir/ritonavir (cipro), ritonavir (cipro), saquinavir (cipro), and neomycin/neomycin (ciprofloxacin). If you are not sure, talk to your doctor or pharmacist.
All medicines can cause side effects. However, the most common side effects are not usually serious.
All medicines can cause other problems. The details of each problem can be found in your doctor’s or pharmacist’s patient information leaflet. You can also check out our.
Inactive ingredients for CiproCiprofloxacin can also be used to treat urinary tract infections, including urinary tract infections of unknown origin, cystitis, and infections of the genitals or anus.
Ciprofloxacin is usually taken twice a day for 3 days, depending on the type and severity of the infection. It is important that you remember to take the medicine. If you take ciprofloxacin more than 6 times a day, you may experience more side effects.
You should not take ciprofloxacin if you are allergic to ciprofloxacin, or if you have ever had an allergic reaction to fluoroquinolones, such as anaphylaxis, lupus, rheumatic fever, or systemic lupus erythematosus (SLE).
Ciprofloxacin can cause side effects in rare cases. Tell your doctor if you are allergic to any of the ingredients listed at the end of this leaflet. Allergic reactions include: skin rash, itching, hives, swelling of your face, lips, tongue, or throat.
Ciprofloxacin comes as a tablet or suspension to take by mouth. Follow the instructions on the packaging carefully. If you are using the liquid medicine, shake the bottle well before each dose and use it for the full prescribed length of time. The liquid medicine may be given with or without food.
CIPROFLOXACIN (ORANTADOL)is an antibiotic used to treat various types of infections caused by bacteria.
Ciprofloxacin (orantibiotics) is the most commonly used antibiotic in the treatment of infections caused by bacteria.
It can be a helpful treatment for the following conditions:
The dosage of Ciprofloxacin depends on the severity of the infection, the condition being treated, and the response to treatment.
Ciprofloxacin, like any other antibiotic, can interact with certain medications. This is because the interaction occurs when there is a decrease in activity of the drug.
Some medicines have effects that do not usually occur with a lower risk of interactions with Ciprofloxacin. Examples include warfarin, digoxin, lithium, phenytoin, rifampin, and some anticoagulants like warfarin and ritonavir.
Ciprofloxacin, like any other antibiotic, can affect the way other drugs work, so it should be avoided.
Take this medicine according to the following dosing instructions. Do not take more than the recommended dose in a 24 hour period.
Ciprofloxacin is usually taken as an oral tablet, taken with or without food. The usual daily dosage is 500 mg. The dosage is gradually increased up to a maximum of 2,000 mg.
Ciprofloxacin should not be given to people who have had an allergic reaction to a group of medicines, such as sulfa drugs or any of the other ingredients of this medicine. This is because a severe reaction to Ciprofloxacin is not expected and this treatment is not recommended in a patient who is allergic to a sulfa drug.
Ciprofloxacin should not be given to patients who have had an allergic reaction to a group of medicines such as sulfa drugs or any of the other ingredients of this medicine.
The most common side effects of Ciprofloxacin include gastrointestinal, skin, and respiratory effects.
Some of the side effects are more likely to occur if you take the medicine with food.
The drug may cause an allergic reaction if taken with a large amount of milk or other dairy products.
Ciprofloxacin can be harmful to an unborn baby if the baby is not given the drug.
Ciprofloxacin, like any other antibiotic, may have effects on the growth of the baby. The use of Ciprofloxacin, like any other antibiotic, can affect the growth of the baby.
The most common side effects of Ciprofloxacin include:
Product name:CIPRO-AOCTgirlfriend
Company name:
DIN:09695699
Status:Marketed
Status date:2004-06-16
| Active ingredient(s) | Strength |
|---|---|
| 250 MG |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Abstract
Background
The use of ciprofloxacin in the treatment of severe infections has been associated with the development of antibiotic-resistant strains of Gram-positive and Gram-negative organisms, leading to the emergence of drug-resistant infections. The objective of this study was to evaluate the antibiotic susceptibility profiles of the four strains ofPseudomonas aeruginosaisolates isolated from a hospital and community-based outpatient community setting in the Netherlands from 2000 to 2005. We evaluated the antibiotic susceptibility ofP. aeruginosastrains isolated from clinical and community-based outpatient facilities with an MIC range of 0.08-0.22 mg/L. Results of the study show that the four strains ofisolates were susceptible to ciprofloxacin, but resistant to other penicillins, fluoroquinolones, tetracyclines, and penicillins with the exception of ceftazidime. The MIC value forwas 0.06 mg/L for ceftazidime and 0.14 mg/L for ciprofloxacin, and the MIC values for ciprofloxacin and ceftazidime were 0.22 and 0.22 mg/L, respectively. The antimicrobial susceptibility of thestrains isolated from hospital and community-based outpatient facilities showed that the MIC ranges were 0.08-0.22 mg/L for ceftazidime and 0.08-0.22 mg/L for ciprofloxacin. The results of this study showed that the antibiotic resistance pattern of thestrains was very similar to that of theEscherichia coliisolated from community-based outpatient facilities. We concluded that ciprofloxacin, fluoroquinolones, tetracyclines, and penicillins are effective and do not cross-react with the antibiotic spectrum of the. Copyright 2021 Elsevier, Inc.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article is distributed in such way that it can be reproduced in any way. For further information, ask the rx developers of this article to PM/e through their email address.The authors are very grateful to the Dutch National Agency for Innovation and Research for providing the opportunity to conduct an open-access version of the study. The Dutch National Agency for Innovation and Research provides funding to implement the research.
CIPROfloxacin is an antimicrobial drug that is effective against a wide range of Gram-positive and Gram-negative pathogens. The objective of this study was to evaluate the antibacterial resistance pattern of the four strains ofisolates isolated from clinical and community-based outpatient facilities in the Netherlands. We evaluated the antibacterial resistance pattern of the four strains ofAll four isolates were susceptible to ciprofloxacin, but resistant to other penicillins, fluoroquinolones, tetracyclines, and penicillins with the exception of ceftazidime. The MIC values for ciprofloxacin were 0.06-0.22 mg/L for ceftazidime and 0.08-0.22 mg/L for ciprofloxacin. The MIC values for ciprofloxacin and ceftazidime were 0.22 and 0.22 mg/L, respectively.strains isolated from hospital and community-based outpatient facilities showed that the MIC ranges were 0.08-0.22 mg/L for ceftazidime and 0.08-0.
The study of antimicrobial resistance, which was a global issue for a long time, has grown exponentially. The study of resistance to various antimicrobials is a challenge because resistance to one type of antimicrobial is quite common. It was observed that the resistance rate of the majority of pathogens, which areStaphylococcus aureus, was more than 100%.
Stade de France Pharmacy